A share price of Abbott Laboratories [ABT] is currently trading at $103.92, up 0.19%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ABT shares have gain 1.17% over the last week, with a monthly amount drifted -1.70%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on May 30, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $121. Previously, Wolfe Research upgraded its rating to Peer Perform on July 21, 2023. On May 30, 2023, downgrade downgraded it’s rating to Equal-Weight but maintained its price target of $112 on the stock. Wolfe Research reiterated its Underperform rating and decreased its price target to $103 on April 20, 2023. UBS reiterated its recommendation of a Buy and raised its price target to $130 on April 20, 2023. Raymond James reiterated a Outperform rating for this stock on April 20, 2023, and upped its price target to $123. In a note dated April 20, 2023, JP Morgan reiterated an Overweight rating on this stock and boosted its target price from $118 to $122.
Abbott Laboratories experienced fluctuations in its stock price throughout the past year between $89.67 and $121.64. Currently, Wall Street analysts expect the stock to reach $130.63 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $103.92 at the most recent close of the market. An investor can expect a potential return of 25.7% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Trailing Twelve Months sales for Abbott Laboratories [NYSE:ABT] were 40.73B which represents 4.00% growth. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.15 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 103.42 points at the first support level, and at 102.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 104.38, and for the 2nd resistance point, it is at 104.83.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Abbott Laboratories [NYSE:ABT] is 1.60. In addition, the Quick Ratio stands at 1.11 and the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 4.44, the price to book ratio is 4.66 and price to earnings (TTM) ratio is 32.77.
Transactions by insiders
Recent insider trading involved Funck, Jr. Robert E., EXECUTIVE VICE PRESIDENT, that happened on May 10 ’24 when 10097.0 shares were sold. EXECUTIVE VICE PRESIDENT, Earnhardt Lisa D completed a deal on May 07 ’24 to sell 22852.0 shares. Meanwhile, EXECUTIVE VICE PRESIDENT Salvadori Daniel Gesua Sive sold 963.0 shares on Mar 01 ’24.
